Skip to main content

Peer Review reports

From: Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations

Original Submission
8 Nov 2022 Submitted Original manuscript
11 Nov 2022 Author responded Author comments - Zhengbo Song
11 Dec 2022 Reviewed Reviewer Report
1 Feb 2023 Reviewed Reviewer Report
12 Feb 2023 Reviewed Reviewer Report
19 Feb 2023 Author responded Author comments - Zhengbo Song
Resubmission - Version 2
11 Nov 2022 Submitted Manuscript version 2
28 Feb 2023 Author responded Author comments - Zhengbo Song
Resubmission - Version 3
28 Feb 2023 Submitted Manuscript version 3
28 Feb 2023 Author responded Author comments - Zhengbo Song
Resubmission - Version 4
28 Feb 2023 Submitted Manuscript version 4
13 Mar 2023 Reviewed Reviewer Report
27 Apr 2023 Author responded Author comments - Zhengbo Song
Resubmission - Version 5
27 Apr 2023 Submitted Manuscript version 5
27 Apr 2023 Author responded Author comments - Zhengbo Song
Resubmission - Version 6
27 Apr 2023 Submitted Manuscript version 6
Publishing
3 May 2023 Editorially accepted
5 May 2023 Article published 10.1186/s12890-023-02466-9

You can find further information about peer review here.

Back to article page